The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?

Smith, Steven J.; Busby, John; Heaney, Liam G.; Pfeffer, Paul; Jackson, David J.; Yang, Freda; Fowler, Stephen J.; Menzies‐Gow, Andrew; Idris, Elfatih; Brown, Thomas; Gore, Robin; Faruqi, Shoaib; Dennison, Paddy; Dodd, James; Mansur, Adel; Priyadarshi, Radhika; Holmes, Joshua; Hearn, AP; Al-Aqqad, Hamsa; Loewenthal, Lola; Cooper, Angela; Fox, Lauren; Selvan, Mayurun; Crooks, Michael G.; Thompson, A. A. Roger; Higbee, Daniel; Fawdon, M.; Nathwani, Vishal; Holmes, Leanne-Jo; Chaudhuri, Rekha

doi:10.1183/23120541.00768-2020

Cited by 17 publications

(22 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, 55% of our SA patients formally shielded according to government mandate Additionally, our SA patients were on high dose inhaled corticosteroids, namely ciclesonide which has been shown to inhibit SARS‐CoV‐2 replication in vitro and attracted interest as a potential COVID‐19 therapy 8 . Our findings for SA mortality were consistent with recently published findings from the UK Severe Asthma Registry 9 …”

Section: Pwnoa Pwa Overall P‐value N = 5724 N = 914 N = 6638 (Pwnoa Vs Pwa)supporting

confidence: 86%

Asthma did not increase in‐hospital COVID‐19‐related mortality in a tertiary UK hospital

Fong

Borca

Phan

et al. 2021

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

To the Editor, Asthma is the most prevalent chronic inflammatory respiratory disease worldwide affecting one in twelve adults (8.3%) in the United Kingdom (UK). 1 Coronavirus disease 2019 (COVID-19) has afflicted at least 80.3 million patients worldwide (17.3 million in the EU, 2.3 million in the UK) and has resulted in more than 1.6 million deaths (427,000 in the EU, 71,000 in the UK) (European Centre for Disease Prevention and Control: 30/12/2020). It is still unclear how asthma affects COVID-19-related mortality with marked regional differences noted. 2 Comorbid associations of COVID-19 with asthma were significantly lower than the prevalence of asthma in

show abstract

Section: Pwnoa Pwa Overall P‐value N = 5724 N = 914 N = 6638 (Pwnoa Vs Pwa)supporting

confidence: 86%

Asthma did not increase in‐hospital COVID‐19‐related mortality in a tertiary UK hospital

Fong

Borca

Phan

et al. 2021

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

“…A large COVID-19 hospitalized Italian population showed that patients with worse COVID-19 outcome (death/need for ventilation vs. discharge at home without requiring invasive procedures) suffered from more severe asthma (GINA 4/ 5, 43 vs. 14%, p = 0.040) [66]. Although biologic-treated patients with asthma typically present with the most severe manifestations of the disease, these studies showed that the number of COVID-19-related admissions and mortality in these patients was strikingly low [67][68][69][70][71][72][73][74]. Treatment with biologicals for severe asthma also seems to have no significant effect on the outcome of COVID- 19.…”

Section: Severe Asthma and Covid-19mentioning

confidence: 90%

Asthma and COVID-19: a dangerous liaison?

Lombardi

Gani²,

Berti

et al. 2021

asthma res and pract

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic, caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), provoked the most striking international public health crisis of our time. COVID-19 can cause a range of breathing problems, from mild to critical, with potential evolution to respiratory failure and acute respiratory distress syndrome. Elderly adults and those affected with chronic cardiovascular, metabolic, and respiratory conditions carry a higher risk of severe COVID-19. Given the global burden of asthma, there are well-founded concerns that the relationship between COVID-19 and asthma could represent a “dangerous liaison”.Here we aim to review the latest evidence on the links between asthma and COVID-19 and provide reasoned answers to current concerns, such as the risk of developing SARS-CoV-2 infection and/or severe COVID-19 stratified by asthmatic patients, the contribution of type-2 vs. non-type-2 asthma and asthma-COPD overlap to the risk of COVID-19 development. We also address the potential role of both standard anti-inflammatory asthma therapies and new biological agents for severe asthma, such as mepolizumab, reslizumab, and benralizumab, on the susceptibility to SARS-CoV-2 infection and severe COVID-19 outcomes.

show abstract

“…In addition, Smith et al . [17] demonstrated worsening mental health in patients with asthma undergoing shielding during the pandemic, and individuals with a history of anxiety or depression were more vulnerable. Our study was designed in response to rapidly defined public health research priorities for people experiencing severe distress during the COVID‐19 pandemic [18,19].…”

Section: Introductionmentioning

confidence: 99%

Health‐related quality of life, uncertainty and coping strategies in solid organ transplant recipients during shielding for the COVID‐19 pandemic

et al. 2021

View full text Add to dashboard Cite

Strict isolation of vulnerable individuals has been a strategy implemented by authorities to protect people from COVID‐19. Our objective was to investigate health‐related quality of life (HRQoL), uncertainty and coping behaviours in solid organ transplant (SOT) recipients during the COVID‐19 pandemic. A cross‐sectional survey of adult SOT recipients undergoing follow‐up at our institution was performed. Perceived health status, uncertainty and coping strategies were assessed using the EQ‐5D‐5L, Short‐Form Mishel Uncertainty‐in‐Illness scale (SF‐MUIS) and Brief Cope, respectively. Interactions with COVID‐19 risk perception, access to healthcare, demographic and clinical variables were assessed. The survey was completed by 826 of 3,839 (21.5%) invited participants. Overall, low levels of uncertainty‐in‐illness were reported, and acceptance was the major coping strategy (92%). Coping by acceptance, feeling protected, self‐perceived susceptibility to COVID‐19 were associated with lower levels of uncertainty. Health status index scores were significantly lower for those with mental health illness, compromised access to healthcare, a perceived high risk of severe COVID‐19 infection and higher levels of uncertainty. A history of mental health illness, risk perceptions, restricted healthcare access, uncertainty and coping strategies were associated with poorer HRQoL in SOT recipients during strict isolation. These findings may allow identification of strategies to improve HRQoL in SOT recipients during the pandemic.

show abstract

The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?

Cited by 17 publications

References 11 publications

Asthma did not increase in‐hospital COVID‐19‐related mortality in a tertiary UK hospital

Asthma did not increase in‐hospital COVID‐19‐related mortality in a tertiary UK hospital

Asthma and COVID-19: a dangerous liaison?

Health‐related quality of life, uncertainty and coping strategies in solid organ transplant recipients during shielding for the COVID‐19 pandemic

Contact Info

Product

Resources

About